Prevalence of diabetes among children treated with growth hormone in Israel.
Adolescent
Child
Child, Preschool
Diabetes Mellitus
/ epidemiology
Female
Follow-Up Studies
Human Growth Hormone
/ adverse effects
Humans
Infant, Small for Gestational Age
Israel
/ epidemiology
Kidney Failure, Chronic
/ drug therapy
Male
Pituitary Hormones
/ deficiency
Prader-Willi Syndrome
/ drug therapy
Prevalence
Recombinant Proteins
/ adverse effects
Risk Factors
Turner Syndrome
/ drug therapy
Journal
Diabetic medicine : a journal of the British Diabetic Association
ISSN: 1464-5491
Titre abrégé: Diabet Med
Pays: England
ID NLM: 8500858
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
accepted:
05
12
2018
pubmed:
29
1
2019
medline:
4
9
2020
entrez:
29
1
2019
Statut:
ppublish
Résumé
To determine the long-term risk of diabetes in a cohort of children treated with recombinant human growth hormone in Israel, using data from the Israeli National Diabetes Register. Between 1988 and 2009, 2513 children were approved for growth hormone treatment. They were assigned to one of two groups. The first group included children treated for isolated growth hormone deficiency and who were small for gestational age and the second included those treated for multiple pituitary hormone deficiency, chronic renal failure, Turner syndrome or Prader-Willi syndrome. The cohort was cross-linked with the Israeli National Diabetes Register for 2014 (mean follow-up duration 12.1±5.3 years), and prevalent cases of diabetes were identified. Standardized prevalence ratios for diabetes were calculated for people aged 10-29 years. In 2014, a total of 23 individuals were identified with diabetes (four with pre-existing diabetes, seven developed diabetes before age 17 years and 12 developed it at a later age). In the isolated growth hormone deficiency and small-for-gestational-age group there was no difference in the prevalence of diabetes compared with the general population (standardized prevalence ratio 2.05, 95% CI 0.94-3.89). In the group that included people with multiple pituitary hormone deficiency, chronic renal failure, Turner syndrome and Prader-Willi syndrome there was a significantly higher diabetes prevalence (standardized prevalence ratio 11.94, 95% CI 6.53-20.00) compared with the general population. No difference in diabetes prevalence was found in the isolated growth hormone deficiency and small-for-gestational-age group, compared with the general population. Children treated with growth hormone with pre-existing risk factors had an increased prevalence of diabetes. It is advisable to monitor blood glucose levels closely during and after growth hormone treatment, especially in such children.
Substances chimiques
Pituitary Hormones
0
Recombinant Proteins
0
Human Growth Hormone
12629-01-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1276-1281Informations de copyright
© 2019 Diabetes UK.
Références
Biasotti A, Houssay BA. Phlorrhizin diabetes in fasting or fed hypophysectomized dogs. J Physiol 1932; 77: 81-91.
Young FG. “Growth” and the Diabetogenic Action of Anterior Pituitary Preparations. Br Med J 1941; 2: 897-901.
Luft R, Olivecrona H. Experiences with hypophysectomy in man. J Neurosurg 1953; 10: 301-316.
Davidson MB. Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev 1987; 8: 115-131.
Holt RI, Simpson HL, Sonksen PH. The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diabet Med 2003; 20: 3-15.
Dreval AV, Trigolosova IV, Misnikova IV et al. Prevalence of diabetes mellitus in patients with acromegaly. Endocr Connect 2014; 3: 93-98.
Raben MS. Preparation of growth hormone from pituitaries of man and monkey. Science 1957; 125: 883-884.
Gibbs CJ, Jr, Joy A, Heffner R, Franko M, Miyazaki M, Asher DM et al. Clinical and pathological features and laboratory confirmation of Creutzfeldt-Jakob disease in a recipient of pituitary-derived human growth hormone. N Engl J Med 1985; 313: 734-738.
Richmond E, Rogol AD. Current indications for growth hormone therapy for children and adolescents. Endocr Dev 2010; 18: 92-108.
Heptulla RA, Boulware SD, Caprio S, Silver D, Sherwin RS, Tamborlane WV. Decreased insulin sensitivity and compensatory hyperinsulinemia after hormone treatment in children with short stature. J Clin Endocrinol Metab 1997; 82: 3234-3238.
Bareille P, Azcona C, Matthews DR, Conway GS, Stanhope R. Lipid profile, glucose tolerance and insulin sensitivity after more than four years of growth hormone therapy in non-growth hormone deficient adolescents. Clin Endocrinol 1999; 51: 347-353.
Crino A, Di Giorgio G, Manco M, Grugni G, Maggioni A. Effects of growth hormone therapy on glucose metabolism and insulin sensitivity indices in prepubertal children with Prader-Willi syndrome. Horm Res 2007; 68: 83-90.
Kappelgaard AM, Kiyomi F, Horikawa R, Yokoya S, Tanaka T. The impact of long-term growth hormone treatment on metabolic parameters in Japanese patients with short stature born small for gestational age. Horm Res Paediatr 2014; 81: 272-279.
Baronio F, Mazzanti L, Girtler Y, Lupi F, Longhi S et al. The influence of GH treatment on glucose homeostasis in girls with Turner Syndrome: a 7 years study. J Clin Endocrinol Metab 2017; 102: 878-883.
Cutfield WS, Wilton P, Bennmarker H, Albertsson-Wikland K, Chatelain P, Ranke MB et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 2000; 355: 610-613.
Woodmansee WW, Hartman ML, Lamberts SW, Zagar AJ, Clemmons DR. Occurrence of impaired fasting glucose in GH-deficient adults receiving GH replacement compared with untreated subjects. Clin Endocrinol 2010; 72: 59-69.
Czernichow P, Albertsson-Wikland K, Tuvemo T, Gunnarsson R. Growth hormone treatment and diabetes: survey of the kabi pharmacia international growth study. Acta Paediatr Scand Suppl 1991; 379: 104-107.
Luger A, Mattsson AF, Koltowska-Haggstrom M, Thunander M, Góth M, Verhelst J et al. Incidence of diabetes mellitus and evolution of glucose parameters in growth hormone-deficient subjects during growth hormone replacement therapy: a long-term observational study. Diabetes Care 2012; 35: 57-62.
Hjerrild BE, Holst JJ, Juhl CB, Christiansen JS, Schmitz O, Gravholt CH. Delayed beta-cell response and glucose intolerance in young women with Turner syndrome. BMC Endocr Disord 2011; 11: 6.
Coupaye M, Tauber M, Cuisset L, Laurier V, Bieth E, Lacorte JM et al. Effect of Genotype and Previous GH Treatment on Adiposity in Adults With Prader-Willi Syndrome. J Clin Endocrinol Metab 2016; 101: 4895-4903.
Stochholm K, Kiess W. Long-term safety of growth hormone-A combined registry analysis. Clin Endocrinol 2018; 88: 515-528.
van Bunderen CC, van Varsseveld NC, Erfurth EM, Ket JC, Drent ML. Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: a systematic review of studies on morbidity. Clin Endocrinol 2014; 81: 1-14.
Saenger P, Attie KM, DiMartino-Nardi J, Hintz R, Frahm L, Frane JW. Metabolic consequences of 5-year growth hormone (GH) therapy in children treated with GH for idiopathic short stature. Genentech Collaborative Study Group. J Clin Endocrinol Metab 1998; 83: 3115-3120.
Laron Z, Klinger B, Anin S, Pertzelan A, Lilos P. Growth during and 2 years after stopping GH treatment in prepubertal children with idiopathic short stature. J Pediatr Endocrinol Metab 1997; 10: 191-196.
Child CJ, Zimmermann AG, Scott RS, Cutler GB, Jr, Battelino T, Blum WF. Prevalence and incidence of diabetes mellitus in GH-treated children and adolescents: analysis from the GeNeSIS observational research program. J Clin Endocrinol Metab 2011; 96: E1025-1034.
Poidvin A, Weill A, Ecosse E, Coste J, Carel JC. Risk of Diabetes Treated in Early Adulthood After Growth Hormone Treatment of Short Stature in Childhood. J Clin Endocrinol Metab 2017; 102: 1291-1298.
Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 2010; 95: 167-177.
Sas T, Mulder P, Aanstoot HJ, Houdijk M, Jansen M, Reeser M et al. Carbohydrate metabolism during long-term growth hormone treatment in children with short stature born small for gestational age. Clin Endocrinol 2001; 54: 243-251.
Baronio F, Mazzanti L, Girtler Y, Tamburrino F, Fazzi A, Lupi F et al. The Influence of Growth Hormone Treatment on Glucose Homeostasis in GrowthHormone-Deficient Children: A Six-Year Follow-Up Study. Horm Res Paediatr 2016; 86: 196-200.
Critical Evaluation of the Safety of Recombinant Human Growth Hormone Administration: Statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 2001; 86: 1868-1870.
Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB et al. Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Horm Res Paediatr 2016; 86: 361-397.